TrialAdvances in therapy2024

Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.

Cécile van Steen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.